{‘She possesses zero expertise’: the US scientific community braces for Dr. Høeg's role at the FDA.

As the United States undertakes unprecedented revisions to its immunization guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations during the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her brief tenure at the FDA.

Proposed Shifts to Childhood Vaccine Program

Agency leaders planned to announce sweeping changes to the pediatric vaccine schedule in December, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of alignment with a large portion of the world with no evidence for public health gain. The announcement has been pushed back until the new year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s CDER, the fifth individual to lead the division this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – typically the domain of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Expertise

Høeg has no obvious track record in drug development, oversight or leadership, which has been customary for past directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a large organization. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that former directors who ran CBER have had.”

This division has an vast range of responsibilities at the agency, she emphasized.

“Many people just pays attention on the innovative therapies, but the generic drug division approves thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be supervised,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major leadership component to the position, which oversees over 5,000 personnel. “It’s a enormous administrative position, if you do it right,” the former official concluded.

Agency Reaction and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among FDA leaders on vaccines, a press secretary said that the “questions are based on incorrect assumptions”.

“Her experience aligns with the functions of her job,” the official explained, citing the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a disputed expedited medication authorization process that apparently troubled her former heads. “By what process are these therapies being picked for this expedited pathway? Who takes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the FDA looks to be trending towards more relaxed rules of most medications, aside from vaccines.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, track record, critics said. She authored a study using unverified volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the new federal leadership included altering rules for novel immunizations and halting “unnecessary” vaccines, she stated following the vote on a online show. At the agency, Høeg has allegedly proposed barring teenage boys from receiving COVID-19 vaccines.

“She is an complete true believer who starts off with her preconceived notions and works backwards to retrofit the science in a very disingenuous, untruthful fashion,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other contrarians, {like|